| Bioactivity | Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity[1]. |
| CAS | 2847102-44-5 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Duvall J R, et al. XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab[J]. Cancer Res, 2022, 82(12_Supplement): 3503-3503. |